Pharmacological characteristics of rosuvastatin: A new HMG-CoA reductase inhibitor;Caractéristiques pharmacologiques de la rosuvastatine, un nouvel antagoniste de 1'HMG-CoA réductase

Therapie

Volumn 58, Issue 2, 2003, Pages 113-121

  Bousquet, Pascal ^a   Gayet, Jean Louis ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b NONE   (France)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase; Hypercholesterolaemia; Pharmacological properties; Rosuvastatin; Tissue selectivity

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0041654460     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003016     Document Type: Article

References (32)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: 4S. Lancet 1994; 344: 1383-9
2. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
3. Tonkin AM, Aylward P, Colquhoun D, et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: LIPID study. N Engl J Med 1998; 339: 1349-57
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS research group. JAMA 1998; 279: 1615-22
6. Kastelein JJ. The future of best practice. Atherosclerosis 1999: 143 Suppl. 1: S17-21
7. Pearson TA, Laurora I, Chu H, et al. A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid lowering therapy and acheiving low density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67
8. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 185-91
9. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-503
10. AFSSAPS. La prise en charge thérapeutique du patient dyslipidémique. Available from URL:http://agmed.sante.gouv.fr/pdf/5/dys2.pdf [Accessed 2003 Apr 29]
11. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adults Treatment Panel III). JAMA 2001; 285: 2486-97
12. Delahaye F, Bory M, Cohen A, et al. Recommandations de la Société Française de Cardiologie concernant la prise en charge de l'infarctus du myocarde après la phase aiguë. Arch Mal Cœur 2001; 94: 697-738
13. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87 Suppl.: 28B-32B
14. Hanefeld M. Clinical rationale for rosuvastatin a potent new HMG-CoA reductase inhibitor. Int J Clin Pract 2001; 55: 399-405
15. Joshi CN, Kakes MG, Serajuddin ATM. Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun 1999; 5: 269-71
16. Goldstein JL, Brown MS. Progress in understanding the LDL receptor and HMGCoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 1984; 25: 1450-61
17. Yokoyama C, Wang X, Briggs MR, et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993; 75: 187-97
18. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells [abstract]. Atherosclerosis 2000; 151 Suppl.: 41
19. Smith G, Davidson R, Bloor S, et al. Pharmacological properties of ZD4522: a new HMG-CoA reductase inhibitor [abstract]. Atherosclerosis 2000: 151 Suppl.: 39
20. Nezasa K, Higaki K, Hasegawa H, et al. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat [abstract]. Atherosclerosis 2000; 151 Suppl.: 39
21. Holdgate GA, Ward WHJ, Davidson RG. et al. Kinetics of inhibition of HMGCoA reductase by new statin, rosuvastatin [abstract]. Atherosclerosis 2001; 2 Suppl.: 166
22. Brown CDA, Windass A, Bleasby K, et al. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract]. Atherosclerosis 2001; 2 Suppl.: 174
23. Havekes L, van der Boom H, Emeis J, et al. New HMG-CoA reductase inhibitor ZD4522 lowers plasma lipids and VLDL production in apoE-3 Leiden transgenic mice [abstract]. Atherosclerosis 2000; 151 Suppl: 172
24. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Brit J Pharmacol 2001; 133: 406-12
25. Warwick MJ, Dane AL, Raza A, et al. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract]. Atherosclerosis 2000; 151 Suppl.: 39
26. Olsson AG, Pears J, Mc Kellar J, et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504-8
27. Berry DA, Berry SM, McKellar J. Bayesian analysis of lipid-lowering potentials of rosuvastatin and atorvastatin [abstract]. Atherosclerosis 2001; 2 Suppl.: 173
28. Davidson M, Ma P, Stein E, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholestérolemia. Am J Cardiol 2002; 89: 268-75
29. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomised double blind study. J Cardiovasc Risk 2001; 18: 383-90
30. Stein E, Strutt KL, Miller E, et al. Rosuvastatin (20, 40 and 80mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80mg) in patients with heterozygous familial hypercholesterolaemia [abstract]. Atherosclerosis 2001; 2 Suppl.: 90-1
31. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002; 89 Suppl.: 50C-7C
32. Stein EA, Lamkin G, Laskarzewski PM, et al. ZD4522 (rosuvastatin) compared with diet and maximal lipid therapy in patients with heterozygotous familial hypercholesterolemia [abstract]. J Am Coll Cardiol 2001; 37 Suppl.: 291A